Targets › ADORA1
19 programs from 19 companies in 28 trials: 11 Phase 4, 7 Phase 2, 7 Phase 1, 3 Phase 3; Other, Cardiovascular, Respiratory; next expected readout Dec 2026.
Receptor for adenosine. The activity of this receptor is mediated by G proteins such as GNAI2 which inhibit adenylyl cyclase. (UniProt, P30542)
Open in Phaseline: the race on ADORA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Region Skane | Adenosine Adenosine receptor agonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Chronic Coronary Syndrome | Dec 2026 |
| National Institute of Cardiovascular Diseases, Pakistan | Adenosine Adenosine receptor agonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | ST-Segment Elevation Myocardial Infarction (STEMI) | Dec 2026 |
| University of Alabama at Birmingham | Caffeine citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Premature Infant Disease | May 2027 |
| Anne E. Zepeski | adenosine Adenosine receptor agonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Supraventricular Tachycardia (SVT) | Jul 2027 |
| Semmelweis University | Caffeine citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Apnea of Prematurity | Dec 2027 |
| Weill Medical College of Cornell University | Adenosine Adenosine receptor agonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Premature Ventricular Contraction (PVC) | Dec 2027 |
| Vastra Gotaland Region | Adenosine Adenosine receptor agonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Takotsubo Syndrome | Dec 2028 |
| RDC Clinical | Caffeine Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 4 | Exercise; Migraine; Healthy; Vibration Therapy … | – |
| NICHD Global Network for Women's and Children's Health | Caffeine Citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 3 | Hypoxic Ischemic Encephalopathy (HIE) | Dec 2029 |
| Rashid Latif Medical College | Adenosine Adenosine receptor agonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 3 | Supraventricular Tachycardia (SVtach) | – |
| New York Medical College | Defibrotide Adenosine A2 receptor agonist; Plasminogen activator; Adenosine A1 receptor agonist | ADORA2B, ADORA2A, PLG, ADORA1, F2 | Phase 2 | Sickle Cell Disease; Sinusoidal Obstruction Syndrome | Dec 2026 |
| Ministry of Health, Saudi Arabia | Caffeine citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 2 | Prematurity | Oct 2027 |
| University of Rochester | Caffeine Citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 2 | Neonatal Apnea | Jul 2028 |
| University of Wisconsin, Madison | Caffeine citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 2 | Kidney Injury | Mar 2030 |
| Indiana University | Caffeine citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 1 | Preterm Labor With Preterm Delivery | Jun 2027 |
| University of Chicago | Caffeine citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 1 | Enhanced Recovery After Surgery in a Pediatric Population | Dec 2027 |
| University of North Carolina, Chapel Hill | Caffeine Citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 1 | Hypoxic-Ischemic Encephalopathy | Jul 2028 |
| McMaster University | Adenosine Adenosine receptor agonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 1 | Chronic Cough (CC) | – |
| Nishtar Medical University | Caffeine Citrate Adenosine receptor antagonist | ADORA1, ADORA2B, ADORA3, ADORA2A | Phase 1 | Apnea of Prematurity | – |
Apnea of Prematurity (3) Hypoxic-Ischemic Encephalopathy (2) Supraventricular Tachycardia (SVT) (1) Premature Infant Disease (1) Sickle Cell Disease (1) Sinusoidal Obstruction Syndrome (1) Exercise (1) Migraine (1) Healthy (1) Vibration Therapy (1) Alzheimer Disease (1) Carcinoma Breast (1)
small molecule (17), protein or peptide (1)
Anne E. Zepeski (1) Semmelweis University (1) University of Alabama at Birmingham (1) New York Medical College (1) RDC Clinical (1) Weill Medical College of Cornell University (1) Vastra Gotaland Region (1) University of Chicago (1) McMaster University (1) Region Skane (1) Indiana University (1) Ministry of Health, Saudi Arabia (1) NICHD Global Network for Women's and Children's Health (1) National Institute of Cardiovascular Diseases, Pakistan (1) University of Wisconsin, Madison (1) Rashid Latif Medical College (1) Nishtar Medical University (1) University of Rochester (1) University of North Carolina, Chapel Hill (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.